Caliper Q1 Receipts Climb 9 Percent as Net Losses Fall by Half
Caliper last week said that total first-quarter revenues increased 9 percent as net loss declined 51 percent.
Total receipts for the three months ended March 31 increased to $18.4 million from $16.9 million in the same period of 2004.
Spending on R&D fell to $3.9 million in the quarter from $6.2 million year over year.
Caliper said net loss for the quarter narrowed to $4.9 million, or $.16 per share, from $10 million, or $.35 per share, in the first quarter of 2004. The company had around $9.9 million in cash and cash equivalents as of March 31.
As reported last month by CBA News, Caliper's Q1 results mark the company's seventh consecutive quarter of year-over-year revenue growth (see CBA News, 4/25/2005).
Dharmacon Will Provide siRNA Library to Millennium
Dharmacon will supply Millennium Pharmaceuticals with a genome-wide short interfering-RNA library corresponding to 22,000 human genes, the companies said last week.
Millennium will use the siRNA library for drug discovery and target validation, said Leland Foster, president and CEO of the Biosciences group of Fisher Scientific International, Dharmacon's parent company.
Dharmacon developed the siRNA library using its SMARTselection and SMART pool technologies, the companies said.
Financial details of the agreement were not disclosed
Beckman's Q1 Revenues Up 7 Percent, Profit Jumps 16 Percent
Beckman Coulter last week reported a 7-percent increase in first-quarter revenues and a 16-percent jump in net earnings.
Revenues for the quarter ended March 31 increased to $576.1 million from $536.8 million during the same period last year. Both the company's Clinical Diagnostics and Biomedical Research divisions contributed about equally to this increase.
Research and development costs remained flat at $48 million.
Beckman's net income for the quarter increased to $41.4 million, or $.62 per share, from $35.6 million, or $.54 per share, during the same period last year. As of March 31, Beckman Coulter had $105.2 million in cash and cash equivalents.
Beckman's new product shipments in Q1 included the Cell Lab IC 100 imaging cytometer.
Invitrogen's Q1 Revenues Up 10 Percent, Earnings Quadruple Thanks to Dynal Purchase
Invitrogen last week reported a 10-percent increase in revenues and quadrupled earnings for the first quarter of 2005.
Revenues for the quarter totaled $277.1 million, up from $251.3 million during the year-ago period. Both Invitrogen's BioDiscovery and BioProduction segments contributed to this increase.
Research and development expenses increased to $21.2 million from $15.7 million during the first quarter of 2004.
The company's net income increased to $47.1 million, or $.82 per share, from $10.5 million, or $.19 per share, during last year's first quarter. Included in this quarter's income is a gain of $21 million related to the hedging activity associated with Invitrogen's acquisition of Dynal.
As of March 31, Invitrogen had $1 billion in cash and investments.
System Biosciences' siRNA Libraries to Be Made Available to Japanese Consortium
System Biosciences said last week that its siRNA libraries targeting the entire human and mouse genomes will be made available to a consortium of Japanese researchers organized by partner B-Bridge International.
The consortium consists of research labs from several institutes, including Osaka University, Nagoya University, the Japanese National Cancer Center, Tokyo Medical University, Ehime University, the Japanese Foundation for Cancer Research, the National Center for Geriatrics and Gerontology, and the National Institute for Advanced Industrial Sciences, SBI said. B-Bridge facilitates and manages this exchange by providing research tools, analysis, and experimental data.